SCHEMBL1810639

SCHEMBL1810639

OCCc1cccc(C2COC2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.41
HDAC4 P56524 1/20 0.40
MEF2D Q14814 1/20 0.40
SLC5A2 P31639 6/20 0.39
CYP4F2 P78329 2/20 0.39
CYP4A11 Q02928 2/20 0.39
DRD2 P14416 3/20 0.38
DRD3 P35462 2/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
DRD5 P21918 1/20 0.38
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ALOX5 P09917 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
BACE1 P56817 1/20 0.36
ACMSD Q8TDX5 1/20 0.35
KIF11 P52732 1/20 0.34
CHRNB4 P30926 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18890109 0.86 DRD2 (0.48) HDAC4MEF2DSLC5A2DRD2DRD3
SCHEMBL23343867 0.84 TDP1 (0.45) TDP1HDAC4SLC5A2CYP4F2CYP4A11
SCHEMBL30543833 0.84 TDP1 (0.45) TDP1HDAC4SLC5A2CYP4F2CYP4A11
SCHEMBL14397228 0.81 PARP1 (0.47) TDP1SLC5A2CYP4F2CYP4A11DRD2
SCHEMBL11673145 0.79 KMO (0.50) TDP1HDAC4CYP4F2CYP4A11DRD2
SCHEMBL30580164 0.79 NCF1 (0.44) HDAC4MEF2DALDH1A1
SCHEMBL25369976 0.79 NCF1 (0.44) HDAC4MEF2DALDH1A1
SCHEMBL21296554 0.76 HDAC4 (0.43) HDAC4MEF2DDRD2DRD3DRD1
SCHEMBL9281772 0.76 TDP1 (0.41) TDP1SLC5A2CYP4F2CYP4A11KDM4E
SCHEMBL20730326 0.74 CYP4F2 (0.38) TDP1SLC5A2CYP4F2CYP4A11DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496556-B1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2018-12-26 EP disclosed
US-9018383-B2 Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2015-04-28 US disclosed
US-20140088158-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2014-03-27 US disclosed
US-8618304-B2 Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2013-12-31 US disclosed
US-20120264790-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-10-18 US disclosed
EP-2496556-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-09-12 EP disclosed
WO-2011053948-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264790-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS LPAR2, LIPG, EDF1 TDP1 3549/4885HDAC4 2201/4885MEF2D 578/4885
US-20140088158-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS LPAR2, LIPG, EDF1 TDP1 3549/4885HDAC4 2201/4885MEF2D 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.